Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses S Elisaf

Showing results (51-60 of 198) with videos related to

Pageof 20
Sort By:
Therapeutic Advances in Endocrinology and Metabolism|February 14, 2015
Dapagliflozin in patients with type 2 diabetes mellitusTheodosios D Filippatos, Evangelos N Liberopoulos, Moses S Elisaf
Journal of the Cardiometabolic Syndrome|February 28, 2009
Statin pleiotropy against renal injuryMichael S Kostapanos, Evangelos N Liberopoulos, Moses S Elisaf
Current Opinion in Lipidology|July 12, 2018
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?Theodosios D Filippatos, Eliza C Christopoulou, Moses S Elisaf
Expert Opinion on Drug Safety|February 23, 2016
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemiaAnastazia A Kei, Theodosios D Filippatos, Moses S Elisaf
World Journal of Nephrology|January 20, 2017
Severe hyperkalemia following blood transfusions: Is there a link?Christos V Rizos, Haralampos J Milionis, Moses S Elisaf
Current Vascular Pharmacology|May 29, 2010
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic reviewEvangelos C Rizos, Aris P Agouridis, Moses S Elisaf
Annals of Clinical and Laboratory Science|September 5, 2006
Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemiaGeorge Miltiadous, Vasilios Saougos, Marios Cariolou, et al.
Expert Opinion on Drug Safety|October 6, 2015
Statins and their increased risk of inducing diabetesAris P Agouridis, Michael S Kostapanos, Moses S Elisaf
Archives of Medical Sciences. Atherosclerotic Diseases|January 31, 2018
Non-hemorrhage-related adverse effects of rivaroxabanEliza C Christopoulou, Theodosios D Filippatos, Moses S Elisaf
Postgraduate Medicine|October 18, 2017
SGLT2 inhibitors: are they safe?Sebastian Filippas-Ntekouan, Theodosios D Filippatos, Moses S Elisaf
Pageof 20

Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Therapeutic Advances in Endocrinology and Metabolism|February 14, 2015
Dapagliflozin in patients with type 2 diabetes mellitusTheodosios D Filippatos, Evangelos N Liberopoulos, Moses S Elisaf
Journal of the Cardiometabolic Syndrome|February 28, 2009
Statin pleiotropy against renal injuryMichael S Kostapanos, Evangelos N Liberopoulos, Moses S Elisaf
Current Opinion in Lipidology|July 12, 2018
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?Theodosios D Filippatos, Eliza C Christopoulou, Moses S Elisaf
Expert Opinion on Drug Safety|February 23, 2016
The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemiaAnastazia A Kei, Theodosios D Filippatos, Moses S Elisaf
World Journal of Nephrology|January 20, 2017
Severe hyperkalemia following blood transfusions: Is there a link?Christos V Rizos, Haralampos J Milionis, Moses S Elisaf
Current Vascular Pharmacology|May 29, 2010
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic reviewEvangelos C Rizos, Aris P Agouridis, Moses S Elisaf
Annals of Clinical and Laboratory Science|September 5, 2006
Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemiaGeorge Miltiadous, Vasilios Saougos, Marios Cariolou, et al.
Expert Opinion on Drug Safety|October 6, 2015
Statins and their increased risk of inducing diabetesAris P Agouridis, Michael S Kostapanos, Moses S Elisaf
Archives of Medical Sciences. Atherosclerotic Diseases|January 31, 2018
Non-hemorrhage-related adverse effects of rivaroxabanEliza C Christopoulou, Theodosios D Filippatos, Moses S Elisaf
Postgraduate Medicine|October 18, 2017
SGLT2 inhibitors: are they safe?Sebastian Filippas-Ntekouan, Theodosios D Filippatos, Moses S Elisaf
Pageof 20